Literature DB >> 24744075

Myasthenia gravis masquerading as dysphagia: unveiled by magnesium infusion.

Jagpal Singh Klair1, Yogita M Rochlani, Nikhil K Meena.   

Abstract

Myasthenia gravis (MG) is a neuromuscular disorder that typically affects the ocular, bulbar, neck, proximal limbs and respiratory muscles. Dysphagia can occasionally be the only presenting symptom leading to extensive but ultimately futile gastrointestinal workup. Delay in diagnosis and use of certain pharmacological agents in the interim can lead to a myasthenic crisis, which though diagnostic is life threatening. We document a case of dysphagia as the only symptom of myasthenia, diagnosed after a magnesium infusion precipitated myasthenic crisis. A 70-year-old Caucasian woman who had had progressive dysphagia for 2 years, for which multiple oesophageal dilations were performed. During a hosptalisation for further gastrointestinal workup, she went into myasthenic crisis (respiratory failure) after receiving magnesium replacement. She required ventilatory support and received five plasma exchange (PLEX) treatments after myasthenia was confirmed by the detection of high antiacetylcholine receptor antibody. Though her symptoms improved, she had a prolonged hospital stay (25 days) and required 18 days of mechanical ventilation. This underscores the morbidity associated with a delay in diagnosis of this condition. This case report suggests that neuromuscular causes should be considered early in elderly patients presenting with dysphagia. Timely diagnosis, initiation of management and avoidance of drugs that affect neuromuscular transmission may help reduce the morbidity and mortality associated with myasthenic crisis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24744075      PMCID: PMC3992550          DOI: 10.1136/bcr-2014-204163

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  An adult patient with new-onset dysphagia.

Authors:  Kieran McIntyre; Simon McVaugh-Smock; Ophyr Mourad
Journal:  CMAJ       Date:  2006-11-07       Impact factor: 8.262

2.  Myasthenia gravis--a rare presentation with tongue atrophy and fasciculation.

Authors:  J Burch; C Warren-Gash; V Ingham; M Patel; D Bennett; K R Chaudhuri
Journal:  Age Ageing       Date:  2006-01       Impact factor: 10.668

Review 3.  Adverse effects of drugs on the respiratory muscles.

Authors:  T K Aldrich; D J Prezant
Journal:  Clin Chest Med       Date:  1990-03       Impact factor: 2.878

Review 4.  Excess magnesium.

Authors:  J P Mordes; W E Wacker
Journal:  Pharmacol Rev       Date:  1977-12       Impact factor: 25.468

5.  Effect of Mg++ on neuromuscular transmission in the Eaton-Lambert syndrome.

Authors:  L Gutmann; M Takamori
Journal:  Neurology       Date:  1973-09       Impact factor: 9.910

6.  Weakness from magnesium-containing cathartics: electrophysiologic studies.

Authors:  T R Swift
Journal:  Muscle Nerve       Date:  1979 Jul-Aug       Impact factor: 3.217

7.  [Drugs that may trigger or exacerbate myasthenia gravis].

Authors:  Ahmed Elsais; Trine Haug Popperud; Øyvind Melien; Emilia Kerty
Journal:  Tidsskr Nor Laegeforen       Date:  2013-02-05

8.  Dysphagia and its consequences in the elderly.

Authors:  L Tibbling; B Gustafsson
Journal:  Dysphagia       Date:  1991       Impact factor: 3.438

9.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

Authors:  Amelia Evoli; Pietro A Tonali; Luca Padua; Mauro Lo Monaco; Flavia Scuderi; Anna P Batocchi; Mariapaola Marino; Emanuela Bartoccioni
Journal:  Brain       Date:  2003-06-23       Impact factor: 13.501

Review 10.  Myasthenia gravis.

Authors:  Nicholas J Silvestri; Gil I Wolfe
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

View more
  1 in total

Review 1.  Acute Respiratory Failure Induced by Magnesium Replacement in a 62-Year-Old Woman with Myasthenia Gravis.

Authors:  Paramveer Singh; Olakunle Idowu; Imrana Malik; Joseph L Nates
Journal:  Tex Heart Inst J       Date:  2015-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.